AUREGEN BIOTHERAPEUTICS
LIVE

Serial Number

79214833

Owner

Auregen BioTherapeutics SA

Attorney

Gary D. Krugman

Filing Date

Apr 13, 2017

Add to watchlist:

No watchlists yet
View on USPTO

AUREGEN BIOTHERAPEUTICS Trademark

Serial Number: 79214833 • Registration: 5521659

AUREGEN BIOTHERAPEUTICS is a trademark filed by Auregen BioTherapeutics SA on April 13, 2017. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Auregen BioTherapeutics SA (3 trademarks)

Avenue Giuseppe-Motta 31-37
Geneva 1202 , CH

Entity Type: 99

Trademark Details

Filing Date

April 13, 2017

Registration Date

July 24, 2018

Published for Opposition

May 8, 2018

Cancellation Date

February 7, 2025

Goods & Services

Biological implants, namely, a vital processed human or animal connective tissue; biological tissue for implantation; cells for medical use; human tissue for allografts; living cells for medical use; implants comprised of living tissue for guided tissue regeneration; implants comprising living tissue; implantable materials comprised of living tissue for use in guided tissue regeneration; skin grafts; surgical implants composed of living tissue; vascular grafts being living tissue; biological molecules to assist with the development of tissue, namely, peptides, polypeptides, nucleosides, amino acids; natural biomaterials for bone and tissue augmentation for medical use; natural biomaterials for bone filling for medical purposes; natural biomaterials for filling cartilage for medical purposes; surgical implants comprising living tissues; biological tissue cultures for medical purposes, all of the aforementioned for in vivo use in the fields of therapeutic and aesthetic treatment

Technical research in the field of biomaterials, 3D bioprinting and tissue engineering; three-dimensional biological printing research; tissue engineering research; scientific and medical research and development in the field of bioprinting; research and development of 3D processes and technology; scientific services relating to the isolation and cultivation of human tissues and cells, excluding services used for a diagnosis; scientific and medical research and development in the field of the manufacture of tissue; development and culture of artificial tissue and cells in the nature of tissue engineering; tissue engineering services; industrial analysis and research services in the field of tissue engineering, all of the aforementioned for in vivo use in the fields of therapeutic and aesthetic treatment

Laboratory apparatus for the manufacture of living tissue and three-dimensional organs, namely, incubators and cell culture apparatus for laboratory use for the manufacture of living tissue and three dimensional organs; laboratory apparatus specially adapted for scientific research performed in laboratories for the manufacture of living tissue and three dimensional organs; bioreactors for cell culture; print heads for ink-jet printers; laboratory equipment for scientific use and research, namely, systems comprising a liquid distributor, an imaging facility being medical imaging equipment, related control software, and related analysis software, all of the aforementioned for in vivo use in the fields of therapeutic and aesthetic treatment

3D printing services; 3D printing services, namely, customized creation of three-dimensional parts using rapid prototyping equipment; 3D biological printing services; biological 3D printing services

Medical services in the field of cellular immunotherapy and transplant, excluding services used for a diagnosis; human cell and tissue bank services; medical services regarding the collection and preservation of cells for medical use, all of the aforementioned for in vivo use in the fields of therapeutic and aesthetic treatment

Filing History

TOTAL INVALIDATION PROCESSED BY THE IB
Apr 16, 2026 INNT
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Mar 30, 2026 INTS
INVALIDATION PROCESSED
Mar 30, 2026 INPC
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Oct 7, 2025 INTR
CANCELLED SECTION 71
Feb 7, 2025 C71T
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Jul 24, 2023 REM3
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Dec 14, 2019 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Dec 14, 2019 REAP
FINAL DECISION TRANSACTION PROCESSED BY IB
Nov 23, 2018 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Nov 6, 2018 FICS
FINAL DISPOSITION PROCESSED
Nov 6, 2018 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Oct 24, 2018 FICR
REGISTERED-PRINCIPAL REGISTER
Jul 24, 2018 R.PR
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
Jun 19, 2018 LIMN
LIMITATION OF GOODS RECEIVED FROM IB
Jun 15, 2018 LIMG
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 8, 2018 NPUB
PUBLISHED FOR OPPOSITION
May 8, 2018 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 18, 2018 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 30, 2018 CNSA
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
Mar 23, 2018 LIMN
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 16, 2018 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 16, 2018 REAP
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 14, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 14, 2018 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 14, 2018 TROA
LIMITATION OF GOODS RECEIVED FROM IB
Dec 22, 2017 LIMG
REFUSAL PROCESSED BY IB
Oct 7, 2017 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Sep 16, 2017 RFCS
REFUSAL PROCESSED BY MPU
Sep 16, 2017 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Sep 13, 2017 RFCR
NON-FINAL ACTION WRITTEN
Sep 12, 2017 CNRT
APPLICATION FILING RECEIPT MAILED
Sep 5, 2017 MAFR
ASSIGNED TO EXAMINER
Aug 31, 2017 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 31, 2017 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Aug 25, 2017 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Aug 24, 2017 REPR